PIMSTONE SIMON N. 4

Accession 0000950170-23-025802

CIK 0001582313other

View on SEC.gov Company Profile

Filed

May 31, 8:00 PM ET

Accepted

Jun 1, 7:25 PM ET

Size

35.9 KB

Accession

0000950170-23-025802

Insider Transaction Report

Form 4

Period: 2023-05-30

Xenon Pharmaceuticals Inc.XENE

PIMSTONE SIMON N.

DirectorPresident, CEO and Director

Transactions

Tax Payment
Common Shares
2023-05-31$38.37/sh−6,165$236,551→ 29,670 total
Exercise/Conversion
Common Shares
2023-06-01$17.76/sh+45,000$799,200→ 51,000 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-05-31−50,000→ 45,000 total
Exercise: $17.76Exp: 2025-03-16→ Common Shares (50,000 underlying)
Sale
Common Shares
2023-05-31$38.53/sh−12,000$462,360→ 6,000 total
Exercise/Conversion
Common Shares
2023-05-31$9.85/sh+29,835$293,875→ 35,835 total
Sale
Common Shares
2023-06-01$38.97/sh−7,458$290,638→ 6,000 total
Tax Payment
Common Shares
2023-06-01$38.53/sh−20,745$799,305→ 30,255 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-05-31−29,835→ 0 total
Exercise: $9.85Exp: 2024-01-13→ Common Shares (29,835 underlying)
Sale
Common Shares
2023-06-01$38.78/sh−24,255$940,609→ 6,000 total
Sale
Common Shares
2023-05-31$38.81/sh−23,670$918,633→ 6,000 total
Sale
Common Shares
2023-05-31$38.69/sh−26,856$1,039,059→ 6,000 total
Exercise/Conversion
Common Shares
2023-06-01$7.69/sh+9,318$71,655→ 15,318 total
Tax Payment
Common Shares
2023-06-01$38.53/sh−1,860$71,666→ 13,458 total
Sale
Common Shares
2023-05-30$39.90/sh−19,000$758,100→ 18,000 total
Sale
Common Shares
2023-05-30$38.63/sh−18,006$695,572→ 37,000 total
Tax Payment
Common Shares
2023-05-31$38.37/sh−23,144$888,035→ 32,856 total
Exercise/Conversion
Common Shares
2023-05-31$17.76/sh+50,000$888,000→ 56,000 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-06-01−9,318→ 30,682 total
Exercise: $7.69Exp: 2025-12-17→ Common Shares (9,318 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-06-01−45,000→ 0 total
Exercise: $17.76Exp: 2025-03-16→ Common Shares (45,000 underlying)

Footnotes (10)

[F1]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $39.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
[F10]The shares subject to the options are fully vested and exercisable.
[F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $40.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
[F3]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.20 to $38.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
[F4]The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
[F5]Represents the closing price of the Company's common shares on May 30, 2023 for purposes of net settlement calculations.
[F6]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.66 to $39.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
[F7]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
[F8]Represents the closing price of the Company's common shares on May 31, 2023 for purposes of net settlement calculations.
[F9]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.78 to $38.81, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

→

Entity typeother

Related Parties

filerCIK 0001620084

Filing Metadata

Form type: 4
Filed: May 31, 8:00 PM ET
Accepted: Jun 1, 7:25 PM ET
Size: 35.9 KB

View on SEC.gov